Related Experiment Video
Updated: Aug 9, 2026
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Therapeutic potential of inhibitory VEGF splice variants
David O Bates1, Steven J Harper
1University of Bristol, Microvascular Research Laboratories, Department of Physiology, Preclinical Veterinary School, Southwell Street, Bristol, BS2 8EJ, UK. dave.bates@bris.ac.uk
Abstract:
Antiangiogenesis by inhibition of vascular endothelial growth factor (VEGF) has recently been demonstrated to be an effective therapeutic mode in human cancer alongside surgery, radiotherapy and chemotherapy. The authors have recently discovered a family of inhibitory VEGF splice variants, which has led to the possibility of using these isoforms as antiangiogenic agents. The discovery, mechanism of action, preclinical evaluation, and the potential uses of these isoforms in future cancer therapy will be discussed herein.
Insights
Researchers discovered inhibitory vascular endothelial growth factor (VEGF) splice variants. These variants offer a novel approach to antiangiogenesis, potentially enhancing future cancer therapies by targeting tumor blood vessel formation.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Antiangiogenesis targeting vascular endothelial growth factor (VEGF) is an established cancer therapy.
- VEGF plays a critical role in tumor angiogenesis and progression.
Purpose of the Study:
- To discuss the discovery of inhibitory VEGF splice variants.
- To explore the potential of these variants as novel antiangiogenic agents for cancer therapy.
Main Methods:
- Discovery of novel VEGF splice variants.
- Preclinical evaluation of antiangiogenic properties.
- Analysis of mechanism of action.
Main Results:
- Identification of a family of inhibitory VEGF splice variants.
- Demonstration of antiangiogenic potential in preclinical models.
Conclusions:
- Inhibitory VEGF splice variants represent a promising new strategy for cancer treatment.
- These isoforms could be developed into effective antiangiogenic agents.
